ISSUE #5 July 9, 2025

The first session was held in Chungbuk on July 8 as part of the nationwide briefing series!

Read More
Watch Now
* You can view both in English using the translation button 😁
∎ Chong Kun Dang leads global drug development with innovative biotechnologies (ChosunBiz)
∎ STgen Bio secures 4.6 billion won contract, boosting pharmaceutical outsourcing efforts (ChosunBiz)
∎ Homegrown blood cancer drug PHI-101 wins ODD in Europe following US (KBR)
∎ ST Pharm signs $18.25 mil. supply deal with 2 US biotechs for oligonucleotide APIs (KBR)
∎ Dong-A ST develops monthly obesity injection DA-1726 with global expansion in sight (ChosunBiz)
∎ SK bioscience completes expansion of new vaccine production facility in South Korea for global market (BioSpectrum Asia)
∎ The world's first successful clinical trial to treat 'interstitial cystitis' (IC), an incurable disease, as a stem cell treatment. (Maeil Business Newspaper)
∎ Samsung to acquire Xealth to expand digital health (The Korea Herald)

β˜… Korea’s listed bio-healthcare companies posted strong growth in Q1 2025, with revenue increasing 16.4% YoYβ€”up from 5.4% in Q1 2024!

The revenue structure also improved, with domestic sales increasing by 7.4% and exports by 38.6% compared to the same period last year.
In particular, the strong growth in exports was driven by expanded overseas sales of biosimilars and CDMO (contract manufacturing) services by major pharmaceutical companies.

β–Ά View related Article

* The full report is available (in Korean only) on the KoreaBIO website (www.koreabio.org)

and the Korea Bioindustry Information Service (www.kbiois.or.kr).
πŸ“°
Join our press list
Get KoreaBIO updates
& media resources
πŸ’¬
Share Your thoughts!
How was your letter today?
βœ‰οΈ
Korean Newsletter
Daily biotech news from Korea and around the world
β€” in Korean
Explore More
KoreaBIO (Korea Biotechnology Industry Organization)
700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea